Chemical name: 1-(((3-(3,4-dihydro-5-methyl)-4-oxo-7-propylimidazo(5,1-f)-as-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine
Formula: C23H32N6O4S
Anabolic activity index: not a steroid
Androgenic activity index: not a steroid

FILITRA-20

Introduction: Filitra-20, manufactured by Fortune Health Care, is a pharmaceutical formulation designed to address erectile dysfunction (ED) in men. It contains Vardenafil as its active ingredient, a potent medication belonging to the class of phosphodiesterase type 5 (PDE5) inhibitors. Filitra-20 offers a reliable solution for men experiencing difficulties achieving or maintaining an erection, facilitating improved sexual performance and satisfaction.

Active Substance: The primary active substance in Filitra-20 is Vardenafil, a selective inhibitor of phosphodiesterase type 5 (PDE5). Vardenafil works by blocking the action of PDE5 enzyme, which is responsible for breaking down cyclic guanosine monophosphate (cGMP), a molecule that regulates blood flow to the penis. By inhibiting PDE5, Vardenafil enhances the effects of cGMP, leading to smooth muscle relaxation, increased blood flow to the penis, and ultimately, an erection.

Form and Packaging: Filitra-20 is available in the form of 10 pills, each containing 20 mg of Vardenafil. The tablets are typically film-coated for ease of swallowing and preservation of the medication. The packaging is designed to ensure the integrity and stability of the tablets, with clear labeling indicating the dosage strength and manufacturer.

Indications: Filitra-20 is indicated for the treatment of erectile dysfunction (ED) in men. It is prescribed to individuals who have difficulty achieving or maintaining an erection sufficient for satisfactory sexual activity. Filitra-20 helps improve erectile function by enhancing blood flow to the penis and promoting a firm and lasting erection.

Mechanism of Action: Vardenafil exerts its therapeutic effects by selectively inhibiting the activity of phosphodiesterase type 5 (PDE5) enzyme. By blocking PDE5, Vardenafil prevents the degradation of cyclic guanosine monophosphate (cGMP), a molecule that relaxes smooth muscle cells in the penile arteries and increases blood flow to the penis. This results in improved erectile function and the ability to achieve and maintain an erection suitable for sexual activity.

Dosage and Administration: The recommended dosage of Filitra-20 for most men is 10 mg taken orally, approximately 25 to 60 minutes before anticipated sexual activity. Depending on individual response and tolerability, the dosage may be adjusted to 5 mg or increased to a maximum of 20 mg per day. Filitra-20 should be taken with a full glass of water and may be taken with or without food. It is essential to follow the prescribed dosage and administration instructions provided by a healthcare professional to ensure optimal treatment outcomes.

Safety Considerations: While Filitra-20 is generally well-tolerated, it may cause certain side effects in some individuals. Common side effects may include headache, flushing, nasal congestion, indigestion, and dizziness. Rare but more severe side effects such as priapism (prolonged erection lasting more than four hours) and sudden vision loss may occur and require immediate medical attention. Patients with pre-existing medical conditions such as cardiovascular disease or liver impairment should exercise caution when using Filitra-20 and consult with a healthcare professional before starting treatment.

Conclusion: Filitra-20, containing Vardenafil as the active substance, offers an effective and convenient treatment option for men with erectile dysfunction (ED). By selectively inhibiting phosphodiesterase type 5 (PDE5) enzyme, Vardenafil enhances blood flow to the penis, facilitating improved erectile function and sexual performance. As with any medication, it is essential for patients to use Filitra-20 under the supervision of a healthcare professional and to adhere to prescribed dosage and administration guidelines to ensure safe and effective treatment outcomes.